AF9 Antibody - BSA Free

Novus Biologicals | Catalog # NB100-1565

Novus Biologicals
100% Guarantee

Key Product Details

Validated by

Independent Antibodies

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot, Immunoprecipitation

Cited:

Western Blot, Immunoprecipitation

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

Format

BSA Free
View all AF9 Primary Antibodies »

Product Specifications

Immunogen

The immunogen recognized by this antibody maps to a region between residues 250 and 300 of human ALL1 Fused Gene from Chromosome 9 Protein using the numbering given in entry NP_004520.1 (GeneID 4300).

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for AF9 Antibody - BSA Free

Western Blot: AF9 Antibody [NB100-1565]

Western Blot: AF9 Antibody [NB100-1565]

Western Blot: AF9 Antibody [NB100-1565] - Detection of Human AF9 on HeLa whole cell lysates using NB100-1565. AF9 was also immunoprecipitated using rabbit anti-AF9 antibodies NB100-1564, NB100-1566 and another AF9 Ab.
Immunohistochemistry-Paraffin: AF9 Antibody [NB100-1565]

Immunohistochemistry-Paraffin: AF9 Antibody [NB100-1565]

Immunohistochemistry-Paraffin: AF9 Antibody [NB100-1565] - Section of human ovarian carcinoma. Antibody: Affinity purified rabbit anti-AF9 used at a dilution of 1:1,000 (1ug/ml). Detection: DAB
AF9 Antibody - BSA Free

Western Blot: AF9 Antibody - BSA Free [NB100-1565] -

Activity of compounds 1–3 on ENL and AF9 in MLL1-r leukemia cells. a–e Levels of ENL, AF9 and beta -actin (as a control) in a–d MV4;11 and e Molm-13 cells upon treatment with compounds 1 (a/d/e), 2 (b), and 3 (c) at the specified concentrations for 24 h, showing they induced degradation of ENL with their dose-responsive curves for calculating DC50 shown at right. AF9 levels were not reduced; f time-dependent degradation of ENL in MV4;11 cells by 1 (500 nM); g–i ENL levels in MV4;11 cells upon pre-treatment for 2 h with SGC-iMLLT (Inh, g), thalidomide (Tha, h) and bortezomib (Bor, i) followed by co-treatment with 1 (500 nM) for 24 h, showing these three compounds can dose-dependently inhibit 1-mediated ENL degradation Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35395864), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
AF9 Antibody - BSA Free

Western Blot: AF9 Antibody - BSA Free [NB100-1565] -

Activity of compounds 1–3 on ENL and AF9 in MLL1-r leukemia cells. a–e Levels of ENL, AF9 and beta -actin (as a control) in a–d MV4;11 and e Molm-13 cells upon treatment with compounds 1 (a/d/e), 2 (b), and 3 (c) at the specified concentrations for 24 h, showing they induced degradation of ENL with their dose-responsive curves for calculating DC50 shown at right. AF9 levels were not reduced; f time-dependent degradation of ENL in MV4;11 cells by 1 (500 nM); g–i ENL levels in MV4;11 cells upon pre-treatment for 2 h with SGC-iMLLT (Inh, g), thalidomide (Tha, h) and bortezomib (Bor, i) followed by co-treatment with 1 (500 nM) for 24 h, showing these three compounds can dose-dependently inhibit 1-mediated ENL degradation Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35395864), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
AF9 Antibody - BSA Free

Western Blot: AF9 Antibody - BSA Free [NB100-1565] -

Activity of compounds 1–3 on ENL and AF9 in MLL1-r leukemia cells. a–e Levels of ENL, AF9 and beta -actin (as a control) in a–d MV4;11 and e Molm-13 cells upon treatment with compounds 1 (a/d/e), 2 (b), and 3 (c) at the specified concentrations for 24 h, showing they induced degradation of ENL with their dose-responsive curves for calculating DC50 shown at right. AF9 levels were not reduced; f time-dependent degradation of ENL in MV4;11 cells by 1 (500 nM); g–i ENL levels in MV4;11 cells upon pre-treatment for 2 h with SGC-iMLLT (Inh, g), thalidomide (Tha, h) and bortezomib (Bor, i) followed by co-treatment with 1 (500 nM) for 24 h, showing these three compounds can dose-dependently inhibit 1-mediated ENL degradation Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35395864), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
AF9 Antibody - BSA Free

Western Blot: AF9 Antibody - BSA Free [NB100-1565] -

Activity of compounds 1–3 on ENL and AF9 in MLL1-r leukemia cells. a–e Levels of ENL, AF9 and beta -actin (as a control) in a–d MV4;11 and e Molm-13 cells upon treatment with compounds 1 (a/d/e), 2 (b), and 3 (c) at the specified concentrations for 24 h, showing they induced degradation of ENL with their dose-responsive curves for calculating DC50 shown at right. AF9 levels were not reduced; f time-dependent degradation of ENL in MV4;11 cells by 1 (500 nM); g–i ENL levels in MV4;11 cells upon pre-treatment for 2 h with SGC-iMLLT (Inh, g), thalidomide (Tha, h) and bortezomib (Bor, i) followed by co-treatment with 1 (500 nM) for 24 h, showing these three compounds can dose-dependently inhibit 1-mediated ENL degradation Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35395864), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
AF9 Antibody - BSA Free

Western Blot: AF9 Antibody - BSA Free [NB100-1565] -

Activity of compounds 1–3 on ENL and AF9 in MLL1-r leukemia cells. a–e Levels of ENL, AF9 and beta -actin (as a control) in a–d MV4;11 and e Molm-13 cells upon treatment with compounds 1 (a/d/e), 2 (b), and 3 (c) at the specified concentrations for 24 h, showing they induced degradation of ENL with their dose-responsive curves for calculating DC50 shown at right. AF9 levels were not reduced; f time-dependent degradation of ENL in MV4;11 cells by 1 (500 nM); g–i ENL levels in MV4;11 cells upon pre-treatment for 2 h with SGC-iMLLT (Inh, g), thalidomide (Tha, h) and bortezomib (Bor, i) followed by co-treatment with 1 (500 nM) for 24 h, showing these three compounds can dose-dependently inhibit 1-mediated ENL degradation Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35395864), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Applications for AF9 Antibody - BSA Free

Application
Recommended Usage

Immunohistochemistry

1:500 - 1:2000

Immunohistochemistry-Paraffin

1:500 - 1:2000

Immunoprecipitation

1-4 ug/mg of lysate

Western Blot

1:5000-1:15000
Application Notes
Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections.

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

Tris-Citrate/Phosphate (pH 7.0 - 8.0)

Format

BSA Free

Preservative

0.09% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C. Do not freeze.

Background: AF9

The human AF9 gene is one of the most common fusion partner genes with the MLL (mixed lineage leukemia) gene resulting in AF9/MLL translocations and leukemogenesis. AF9 is highly homologous to the gene product of ENL, another common MLL fusion partner gene. The function of AF9 is not known but through studies of ENL it is proposed to be a nuclear transactivating factor. AF9 is also known as ALL1 Fused Gene from Chromosome 9 Protein, MLLT3, Myeloid/Lymphoid or Mixed-Lineage Leukemia Translocated 3, YEATS3, and FLJ2035.

Alternate Names

AF-9, AF9myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog);translocated to, 3, ALL1-fused gene from chromosome 9 protein, myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog); translocatedto, 3, myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila);translocated to, 3, Myeloid/lymphoid or mixed-lineage leukemia translocated to chromosome 3 protein, protein AF-9, YEATS domain-containing protein 3, YEATS3FLJ2035

Entrez Gene IDs

4300 (Human)

Gene Symbol

MLLT3

UniProt

NP_004520.1 (Human)

Additional AF9 Products

Product Documents for AF9 Antibody - BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Download SDS

Product Specific Notices for AF9 Antibody - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Citations for AF9 Antibody - BSA Free

Customer Reviews for AF9 Antibody - BSA Free

There are currently no reviews for this product. Be the first to review AF9 Antibody - BSA Free and earn rewards!

Have you used AF9 Antibody - BSA Free?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 for a review with an image

$10/€7/£6/$10CAN/¥1110 for a review without an image

Submit a review
Amazon Gift Card

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies